Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: A retrospective study

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 3, 2011, Pages 727-733

  Rosato, E ^a   Rossi, C ^a   Molinaro, I ^a   Giovannetti, A ^a   Pisarri, S ^a   Salsano, Felice ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Interstitial lung disease; N acetylcysteine; Pulmonary fibrosis; Pulmonary function tests; Systemic sclerosis

Indexed keywords

ACETYLCYSTEINE; CARBON MONOXIDE; NIFEDIPINE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; CARBON MONOXIDE DIFFUSING CAPACITY; FINGER ULCER; FLUSHING; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEADACHE; RAYNAUD PHENOMENON; RESPIRATORY TRACT PARAMETERS; SIDE EFFECT; TREATMENT DURATION; VITAL CAPACITY;

EID: 80055101619     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400319     Document Type: Article

References (21)

1. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4:351-68.
2. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132:1311-21. (Pubitemid 47621009)
3. Tufvesson E, Bozovic G, Hesselstrand R, Bjermer L, Scheja A, Wuttge DM. Increased cysteinyl-leukotrienes and 8-isoprostane in exhaled breath condensate from systemic sclerosis patients. Rheumatology 2010; 49:2322-6.
4. Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79:1665-73. (Pubitemid 17117272)
5. Demedts M, Behr J, Buhl R, et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-42. (Pubitemid 41697286)
6. Behr J, Demedts M, Buhl R, et al.; IFIGENIA study group. Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Respir Res 2009; 10:101.
7. Furst DE, Clements PJ, Hanis R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979; 38:356-61. (Pubitemid 9255311)
8. Rosato E, Borghese F, Pisarri S, Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 2009; 28:1379-84.
9. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
10. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1998; 15:202-5.
11. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J 1993; 16(S):1-100.
12. Roca J, Whipp B (chairmen): ERS Task Force on Standardization of Clinical Exercise Testing. Clinical exercise testing with reference to lung disease: indications, standardization and interpretation strategies. Eur Respir J 1997; 10:2662-89. (Pubitemid 28048650)
13. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169:977-83. (Pubitemid 27406888)
14. Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, Gabrielli A. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001; 28:2257-62. (Pubitemid 32947872)
15. Rosato E, Cianci R, Barbano B, et al. N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis. Acta Pharmacol Sin 2009; 30:1283-8.
16. Rosato E, Zardi EM, Barbano B, et al. N-acetylcysteine infusion improves hepatic perfusion in the early stages of systemic sclerosis. Int J Immunopathol Pharmacol. 2009; 22:763-72.
17. Salsano F, Letizia C, Proietti M, Rossi C, Proietti AR, Rosato E, Pisarri S. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon. Int J Immunopathol Pharmacol. 2005; 18:761-70.
18. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, Gabrielli A. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44:2653-64. (Pubitemid 33049343)
19. Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63:783-94.
20. Magro CM, Ross P, Marsh CB, Allen JN, Liff D, Knight DA, Waldman WJ, Cowden DJ. The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol. 2007; 127:237-47. (Pubitemid 46797181)
21. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 2002; 277:3101-8. (Pubitemid 34953170)